Reality Check on Major Depressive Disorder
Market access for major depressive disorder treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, more than 47% of the covered lives under commercial formularies have utilization management restrictions
- Class Trends: In November 2018, CMS issued a proposed rule that would let Medicare Advantage and Part D plans limit coverage of certain drugs in the six "protected classes," which include antidepressants and antipsychotics. Wall Street analysts viewed the proposal as good news for managed care firms
- Key Findings: In a market that is surrounded by strong oral generics and numerous patent expirations, competition of brand-name products is increasing
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.